5Mourao-Junior CA, Sa JR, Guedes OM, et al. Effects of metformin onthe glycemic control, lipid profile, and arterial blood pressure of type 2diabetic patients with metabolic syndrome already on insulin[J]. Braz JMed Biol Res,2006,39(4) :489-494.
7Bell DS. A comparison of agents used to manage type 2 diabetes mellitus : need for reappraisal of traditional approaches. Treat Endocrinol, 2004,3:67-76.
8Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus:the results of continuous glucose monitoring. Diabetes Technol Ther,2003,5 : 19-26.
9Amin R, Ross K, Acerini CL, et al. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen:use of continuous glucose monitoring system. Diabetes Care, 2003,26:662-667.
10Pramming S, Thorsteinsson B, Bendtson I, et al. Nocturnal hypoglycemia in patients receiving conventional treatment with insulin.BMJ, 1985,291:376-379.
1Reinhart L,Panning CA.Insulin glargine:a new long-acting insulinproduct[J].Am J Health Syst Pharm,2002,59:643-649.
2Marchetti P,Del Guerra S,Marselli L,et al.From type 2 diabetic pa-tients have functional defects and increased apoptosis that are amelio-rated by metformin[J].J Clin Endocrinol Metab,2004,89:5535-5541.
3Jacobsen L,Sogaard B,Riis A.Pharmacokinetics and pharmacodynamicsof a premixed formulation of soluble and protamine retarded insulinaspart[J].Eur J Clin Pharmacol,2000,56(5):399-403.
4Purrello F,Rabuazza AM.Metabolic factors that affect beta-cellfunction and survival[J].Diabet Nutr Metab,2000,13(2):84-91.
